VIP: Real Biology, an Investigational Drug, and the CIRS Question

VIP sits at an unusual intersection. It is a real, well-studied human peptide with decades of legitimate science behind it; it is the basis for an investigational drug that made headlines during the COVID-19 pandemic; and it is the centerpiece of a treatment protocol for a condition that mainstream medicine does not broadly recognize. Each of those is true at once, and the marketing around VIP tends to blur them into a single, more confident story than the evidence supports. This guide keeps them separate. It covers what VIP is and does, what the synthetic drug aviptadil has and has not shown, how strong the evidence really is for the popular intranasal use in chronic inflammatory response syndrome (CIRS, or "mold illness"), and how to verify what you are buying. For product-level detail, the VIP guide is the companion reference; this article is about the science and the state of the evidence.

One distinction runs underneath all of it: a molecule having genuine biology is not the same as a proven therapy, and purity, safety, and effectiveness are three separate questions. A lab test confirms what is in a vial, not whether a compound is safe for you or whether it works.

What is VIP?

VIP, short for vasoactive intestinal peptide, is a 28-amino-acid neuropeptide in the same family as glucagon and secretin. First isolated from the intestine in 1970 by Said and Mutt, it is made by nerve cells throughout the gut, brain, and peripheral nervous system, as well as in the lungs and immune cells. Despite the name, its effects reach far beyond the gut: it acts through receptors called VPAC1 and VPAC2 as a wide-ranging signaling molecule, which is exactly why it has drawn interest across so many conditions, from lung injury to autoimmune disease.

That breadth is part of why VIP is easy to market and hard to pin down. A molecule that touches the vascular, respiratory, immune, and nervous systems can be attached to almost any wellness claim, so the useful question is not "what can VIP affect" but "what has actually been shown in people."

What does VIP do in the body?

VIP is what biologists call pleiotropic: it does many different things. It relaxes blood vessels and airways, supports the lung cells that produce surfactant, and helps regulate the sleep-wake clock and protect nerve cells. Its most-studied role for therapeutic purposes is immune: VIP is broadly anti-inflammatory, pushing the immune balance toward regulatory T cells and a calmer state and lowering inflammatory signals like TNF-alpha, a role laid out in the research on VIP's modulation of innate immunity. In animal models of autoimmune disease, arthritis, and septic shock, VIP has shown protective effects, with work such as Delgado and colleagues' studies on regulatory T-cell induction (2005) and Gonzalez-Rey and colleagues' work in experimental autoimmune encephalomyelitis (2006). This preclinical record is the foundation most of VIP's proposed uses build on.

These are real functions, and VIP sits within the broader immune and longevity peptide category alongside other immune-modulating compounds such as thymosin alpha-1. The gap, as always, is between what a molecule does in a dish or a mouse and what it does for a person, and that is where VIP's story gets more honest and less tidy.

Aviptadil: VIP as an investigational drug

Aviptadil is synthetic VIP, developed as a drug under the names RLF-100 and ZYESAMI. It has received FDA Orphan Drug Designation for ARDS and pulmonary hypertension and Fast Track Designation for COVID-19 respiratory failure, and those labels are often quoted as if they were approvals. They are not. A designation is a development incentive or an expedited-review status, not a finding that a drug works. In the large phase 2b/3 trial of intravenous aviptadil for critical COVID-19, the primary endpoint did not reach statistical significance, meaning no clear difference from placebo, and aviptadil remains unapproved for any use in the United States.

This distinction trips up a lot of readers, because "FDA Fast Track" sounds like an endorsement. It is worth being precise about what each label actually means.

Beyond COVID-19, aviptadil has been studied in small, early-phase work for conditions such as sarcoidosis and pulmonary hypertension, and a VIP-based combination product is approved in some countries for erectile dysfunction. The honest summary of the drug side is that aviptadil is a legitimate compound in genuine clinical development that has not yet demonstrated clear efficacy in a controlled trial for the indications it is best known for.

VIP and CIRS: what does the evidence show?

Within the peptide community, VIP is best known for the Shoemaker protocol for chronic inflammatory response syndrome (CIRS), or "mold illness," where a compounded intranasal VIP spray is used as the final step. This is the demand the compound is riding, and it deserves an honest look rather than either a sales pitch or a dismissal. The supporting studies are small, open-label, and uncontrolled, published largely by the protocol's originator in lower-tier journals, with patients often serving as their own comparison rather than being measured against a placebo group. CIRS itself is not a widely accepted diagnosis in mainstream medicine, and its diagnostic framework is largely associated with the same source as the treatment.

None of this proves VIP does nothing for the people who use it, and it is not a judgment about anyone's symptoms, which are real regardless of the label attached to them. What it means is that the evidence is weak and contested, not settled, and that the confidence with which intranasal VIP is often presented for CIRS runs well ahead of the quality of the studies behind it. Anyone considering it should know they are entering an area where the science is preliminary and the diagnosis is disputed, and should weigh that honestly with a clinician rather than relying on protocol literature alone.

So what does the evidence support?

Putting the pieces together: VIP has genuine, well-characterized biology and a real preclinical anti-inflammatory record, aviptadil is a legitimate investigational drug, and yet the controlled human evidence that it treats any specific condition is thin. The flagship COVID-19 trial missed its primary endpoint, the sarcoidosis and pulmonary-hypertension data are early and small, and the CIRS use rests on weak studies for a contested diagnosis. The honest position is that VIP is scientifically interesting and largely unproven as a therapy, and the marketing around it tends to skip that second half.

The point of laying it out this way is not to say VIP is worthless; it is to match confidence to evidence. The biology is real, the drug is real, and the proof that it helps a given condition is, for now, mostly missing.

Is VIP legal and regulated?

Aviptadil is not approved by the FDA for any indication; it remains investigational. The intranasal VIP used for CIRS is a compounded medication, prepared by compounding pharmacies and prescribed off-label by clinicians who work within that framework, rather than a standard approved product, and VIP sold in the broader research-peptide market has no medical approval at all. One VIP-based product, combined with another drug for erectile dysfunction, is approved in some countries but not universally.

As with the other compounds covered here, legal status varies by country and shifts over time, which the country-by-country legal status overview addresses in more detail. Treat any regulatory statement here as a snapshot to re-check before acting on it.

How do you know the VIP you're buying is real?

VIP presents a particular verification challenge because it is chemically fragile: it degrades readily, even at room temperature, which matters for both lab samples and the product itself. Independent third-party testing is the only way to confirm a vial's contents, and for VIP that means an HPLC purity result plus a mass-spectrometry identity confirmation from a named laboratory, not a seller's own claim. Across the independent VIP tests Peptigrity has aggregated — thirty-six as of June 2026, averaging 99.36 percent purity — most clear 99 percent, but the spread is wider than for many peptides, with individual results dipping below 98 percent, consistent with VIP being a longer, harder peptide to make cleanly.

There is also a catch specific to how VIP is actually used. An HPLC purity figure describes the raw peptide, not a finished intranasal spray, and the stability and excipient questions that come with a nasal formulation are not captured by a basic peptide test, so for the CIRS use in particular, a strong purity number on the powder does not guarantee a stable, intact product at the point of use. Purity, to return to the distinction this article opened with, describes only what is in the vial, not whether the contents are safe for you or effective for any purpose. The warning signs covered in the guide to Certificate of Analysis red flags and the workflow in how peptide testing works are worth understanding first. Peptigrity aggregates independent VIP lab tests so that purity and identity can be compared across sources rather than taken on a seller's word.

Frequently Asked Questions

Is aviptadil FDA-approved?

No. It has Orphan Drug and Fast Track designations, which are development and review statuses, not approvals, and it remains investigational and unapproved for any use. The designations are often quoted as if they settled the question of whether it works; they do not.

Did VIP work for COVID-19?

The large controlled trial of intravenous aviptadil did not meet its primary endpoint, so it did not demonstrate clear benefit over placebo, and it was not approved for COVID-19. Early open-label reports looked more encouraging, which is a common pattern that controlled trials exist to test.

Does VIP nasal spray help with mold illness (CIRS)?

The evidence is weak and contested: small, uncontrolled studies, mostly from the protocol's originator, for a diagnosis mainstream medicine does not broadly accept. That does not invalidate anyone's symptoms, but it does mean the treatment is far from proven.

What does VIP actually do?

It is a wide-ranging signaling peptide, with effects on blood vessels, airways, the immune system, circadian rhythm, and nerve protection, and a genuine preclinical anti-inflammatory record. Its broad biology is well established; its proven human therapeutic uses are limited.

Why is VIP hard to keep stable?

It degrades easily, including at room temperature, so storage and handling matter and make independent identity and purity testing especially worthwhile. A degraded product may not contain what the label claims even if it once did.

This article is for educational and informational purposes only and is not medical advice. VIP's synthetic form, aviptadil, is investigational and is not approved by the FDA, the EMA, or other regulators; its large COVID-19 trial did not meet its primary endpoint. Intranasal VIP for CIRS is a compounded, off-label use supported only by small, uncontrolled studies, for a condition that is not a widely accepted mainstream diagnosis. FDA Orphan Drug and Fast Track designations are not approvals and do not indicate that a drug is effective. Purity and identity testing describe only what is in a vial, not whether a product is safe or effective. Regulatory status was verified as of June 2026 and should be re-checked before relying on it. Always consult a qualified healthcare provider before making any decision about a peptide.